CS-0159 is under clinical development by Cascade Pharmaceuticals and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CS-0159’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CS-0159 overview

CS-0159 is under development for the treatment of primary sclerosing cholangitis, nonalcoholic steatohepatitis (NASH), inflammatory bowel disease and primary biliary cholangitis. It is administered through oral route. It acts by targeting farnesoid X receptor (FXR).

Cascade Pharmaceuticals overview

Cascade Pharmaceuticals is a pharmaceutical research and development enterprise that focusing on the early discovery, drug development and subsequent commercialization of innovative drugs for nuclear receptors. The company is headquartered in Shanghai, China.

For a complete picture of CS-0159’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.